Erratum to “Frizzled-10 Extracellular Vesicles Plasma Concentration Is Associated with Tumoral Progression in Patients with Colorectal and Gastric Cancer”
In the article titled “Frizzled-10 Extracellular Vesicles Plasma Concentration Is Associated with Tumoral Progression in Patients with Colorectal and Gastric Cancer” [1], there was an error in Figures 1 and 3. Because of an error in figure assembly after acceptance, in Figure 1, the two images (a1) and (b1) were identical, and in Figure 3, the expression of the CD63 was missing.
The correct figures should be as follows:
Figure 1
Analysis of morphology and size distribution of freshly isolated sEVs performed by TEM, SEM, and DLS investigation. Representative TEM micrographs obtained with positive (a, b, c) and negative (a1, b1, c1) staining of sEVs extracted from plasma of the healthy donors (a, a1) and the CRC (b, b1) and GC (c, c1) patients, along with their corresponding SEM images (inset a, b, c). Related size distributions by TEM (a2, b2, c2) and DLS (a3, b3, c3) analysis.
Figure 3 (a)
Detection and determination of FZD-10 expression levels in sEVs isolated from cancer patients with metastasis by Western blotting and densitometry analysis. Representative Western blotting of FZD-10 and three exosomal/EV protein markers (Hsp70, CD-63, and ALIX) in sEVs extracted from patients with metastatic GC (Px GC) and metastatic CRC (Px CRC), before surgery and at different treatment steps. Molecular mass markers are indicated on the right. The same load (20 μg) of samples based on total protein content (a). Semiquantitative evaluation of relative FZD-10 expression in sEVs extracts by densitometry analysis of protein bands in (a). FZD-10 bands were measured and normalized with corresponding housekeeping Hsp70 bands, for each CRC and GC patient (three replicates). Average value of FZD-10 expression levels among all CRC or GC or metastastic CRC patients reported in graph. p < 0.005 versus healthy control. n = 6 for CRC, n = 6 for GC, and n = 8 for healthy donors (b).
Figure 3 (b)
Detection and determination of FZD-10 expression levels in sEVs isolated from cancer patients with metastasis by Western blotting and densitometry analysis. Representative Western blotting of FZD-10 and three exosomal/EV protein markers (Hsp70, CD-63, and ALIX) in sEVs extracted from patients with metastatic GC (Px GC) and metastatic CRC (Px CRC), before surgery and at different treatment steps. Molecular mass markers are indicated on the right. The same load (20 μg) of samples based on total protein content (a). Semiquantitative evaluation of relative FZD-10 expression in sEVs extracts by densitometry analysis of protein bands in (a). FZD-10 bands were measured and normalized with corresponding housekeeping Hsp70 bands, for each CRC and GC patient (three replicates). Average value of FZD-10 expression levels among all CRC or GC or metastastic CRC patients reported in graph. p < 0.005 versus healthy control. n = 6 for CRC, n = 6 for GC, and n = 8 for healthy donors (b).
